Patents Assigned to Teva Pharmaceuticals USA, Inc.
-
Patent number: 11826322Abstract: The invention relates to a pre-filled syringe, an auto-injector device comprising such pre-filled syringe, a method of administering a pharmaceutical composition with such auto-injector device, and a manufacturing method for such auto-injector device. The pre-filled syringe comprises a container and a needle. The container is filled with a pharmaceutical composition comprising epinephrine, a buffer, and water. The buffer is configured to buffer in a pH range between 3 and 4. The needle is adhered to the container by means of a urethane acrylate or urethane methacrylate acrylic light cure adhesive, which is configured to provide a pull out resistance of the needle relative to the container which is between 30 N to 100 N, preferably between 50 N to 70 N, more preferably greater than 60 N after 90 days exposure to the pharmaceutical composition at 40° C. and 75% relative humidity (RH). In an example, the pharmaceutical composition is for the treatment of an anaphylactic event.Type: GrantFiled: August 20, 2020Date of Patent: November 28, 2023Assignee: Teva Pharmaceuticals USA, Inc.Inventors: Vijay Joguparthi, Rosario LoBrutto
-
Patent number: 10835503Abstract: The invention relates to a pre-filled syringe, an auto-injector device comprising such pre-filled syringe, a method of administering a pharmaceutical composition with such auto-injector device, and a manufacturing method for such auto-injector device. The pre-filled syringe comprises a container and a needle. The container is filled with a pharmaceutical composition comprising epinephrine, a buffer, and water. The buffer is configured to buffer in a pH range between 3 and 4. The needle is adhered to the container by means of a urethane acrylate or urethane methacrylate acrylic light cure adhesive, which is configured to provide a pull out resistance of the needle relative to the container which is between 30 N to 100 N, preferably between 50 N to 70 N, more preferably greater than 60 N after 90 days exposure to the pharmaceutical composition at 40° C. and 75% relative humidity (RH). In an example, the pharmaceutical composition is for the treatment of an anaphylactic event.Type: GrantFiled: January 13, 2017Date of Patent: November 17, 2020Assignee: TEVA PHARMACEUTICALS USA, INC.Inventors: Vijay Joguparthi, Rosario LoBrutto
-
Patent number: 10640487Abstract: The present disclosure relates to solid state forms of Nilotinib fumarate and Nilotinib hydrochloride L-tartaric acid co-crystals, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: March 13, 2017Date of Patent: May 5, 2020Assignee: Teva Pharmaceuticals USA, Inc.Inventors: Helena Ceric, Igor Avdejev, Edi Topic
-
Patent number: 10035802Abstract: The present invention encompasses solid state forms of Ibrutinib, including forms G, J and K, and pharmaceutical compositions thereof.Type: GrantFiled: August 13, 2015Date of Patent: July 31, 2018Assignee: TEVA PHARMACEUTICALS USA, INC.Inventors: Meital Cohen, Yuval Cohen, Ariel Mittelman, Elana Ben Moha-Lerman, Idit Tzanani, Leonid Levenfeld
-
Publication number: 20160324943Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.Type: ApplicationFiled: August 26, 2015Publication date: November 10, 2016Applicant: TEVA PHARMACEUTICALS USA, INC.Inventors: Avi TOVI, Chaim EIDELMAN, Shimon SHUSHAN, Alon HAGI, Alexander IVCHENKO, Gabriel-Marcus BUTILCA, Leah BAR-OZ, Tehila GADI, Gil ZAOVI
-
Publication number: 20150058039Abstract: A platform accessible by a user from a web browser/HMO's electronic medical record (EMR) for providing the user with information regarding a patient's drug regimen as well as generating alerts concerning potential adverse effects to a patient from taking a cluster including a plurality of pharmaceutical preparations and various food supplements/herbals may be in data communication with and configured to obtain information from at least two databases and at least one tool for processing the cluster of pharmaceutical preparations in accordance with the information to generate the alerts to the user.Type: ApplicationFiled: March 8, 2012Publication date: February 26, 2015Applicant: TEVA PHARMACEUTICALS USA, INC.Inventor: Ron Zeev Shiloh
-
Publication number: 20140050784Abstract: The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Applicants: TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD.Inventors: Elena KAGAN, Nitzan SHAHAR, Elina HARONSKY, Gregg R. DEROSA
-
Patent number: 8609856Abstract: New forms of Febuxostat have been prepared and characterized. These forms are useful, for example, in the chronic management of hyperuricemia in patients with gout.Type: GrantFiled: March 1, 2013Date of Patent: December 17, 2013Assignee: Teva Pharmaceuticals USA, Inc.Inventors: Maytal Piran, Leonid Metsger
-
Publication number: 20130203674Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.Type: ApplicationFiled: March 25, 2013Publication date: August 8, 2013Applicant: TEVA Pharmaceuticals USA, Inc.Inventor: TEVA Pharmaceuticals USA, Inc.
-
Publication number: 20130196919Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.Type: ApplicationFiled: March 25, 2013Publication date: August 1, 2013Applicant: TEVA Pharmaceuticals USA, Inc.Inventor: TEVA Pharmaceuticals USA, Inc.
-
Publication number: 20130196917Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.Type: ApplicationFiled: March 25, 2013Publication date: August 1, 2013Applicant: TEVA Pharmaceuticals USA, Inc.Inventor: TEVA Pharmaceuticals USA, Inc.
-
Publication number: 20130196920Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.Type: ApplicationFiled: March 25, 2013Publication date: August 1, 2013Applicant: TEVA Pharmaceuticals USA, Inc.Inventor: TEVA Pharmaceuticals USA, Inc.
-
Publication number: 20130196918Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.Type: ApplicationFiled: March 25, 2013Publication date: August 1, 2013Applicant: TEVA Pharmaceuticals USA, Inc.Inventor: TEVA Pharmaceuticals USA, Inc.
-
Publication number: 20130196916Abstract: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably having a purity of at least about 99.0% by HPLC, wherein the total impurities amount to less than 1.0%, comprising not more than 0.5% [Asp9-Bivalirudin] and each impurity is less than 0.5%.Type: ApplicationFiled: March 25, 2013Publication date: August 1, 2013Applicant: TEVA Pharmaceuticals USA, Inc.Inventor: TEVA Pharmaceuticals USA, Inc.
-
Patent number: 8415481Abstract: New forms of Febuxostat have been prepared and characterized. These forms are useful, for example, in the chronic management of hyperuricemia in patients with gout.Type: GrantFiled: June 10, 2010Date of Patent: April 9, 2013Assignee: Teva Pharmaceuticals USA, Inc.Inventors: Maytal Piran, Leonid Metsger
-
Publication number: 20120238555Abstract: This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which exhibits a dissolution profile according to which greater than about 85% of the Irbesartan is dissolved within about 30 minutes using USP apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37° C. with paddle speed of 50 rpm. The formulation can optionally contain at least one additional active ingredient.Type: ApplicationFiled: May 31, 2012Publication date: September 20, 2012Applicant: TEVA PHARMACEUTICALS USA, INC.Inventors: Gershon Kolatkar, Erela Zisman
-
Publication number: 20120220663Abstract: The present invention provides polymorphic forms of aliskiren hemifumarate, and processes for preparation thereof and for the preparation of the amorphous form of aliskiren hemifumarate. The present invention also provides pharmaceutical compositions comprising the aliskiren hemifumarate crystalline forms T1, T3 or T4, T5, T6, T7, T8 and at least one pharmaceutically acceptable excipient, and the use of these pharmaceutical compositions in the treatment of hypertension.Type: ApplicationFiled: September 2, 2010Publication date: August 30, 2012Applicants: TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD.Inventors: Marina Etinger, Rinat Moshkovits Kaptsan, Ariel Mittelman
-
Patent number: 8222282Abstract: Flupirtine acid addition salts having the following formula (2), wherein R represents a substituted or unsubstituted C1-C12-alkyl or a substituted or unsubstituted C6-C10-aryl group, have been prepared.Type: GrantFiled: June 9, 2009Date of Patent: July 17, 2012Assignee: Teva Pharmaceuticals USA, Inc.Inventors: Christoph Martin Hoock, Asal Qadan
-
Publication number: 20100076195Abstract: The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.Type: ApplicationFiled: August 24, 2009Publication date: March 25, 2010Applicants: TEVA PHARMACEUTICAL INDUSTRIES LTD., TEVA PHARMACEUTICALS USA, INC.Inventors: Greta STERIMBAUM, Evgeny SHAPIRO, Kobi CHEN
-
Publication number: 20100056583Abstract: The present invention provides crystalline forms of Rosiglitazone hydrobromide, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms.Type: ApplicationFiled: August 21, 2009Publication date: March 4, 2010Applicants: TEVA PHARMACEUTICAL INDUSTRIES LTD., TEVA PHARMACEUTICALS USA, INC. - for assignment of rights in BarbadosInventors: Vinod Kumar Kansal, Harish Ranjan, Sanjay Nayal, Michal Rafilovich